Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

The final patient population for whom ACIP recommends Merck’s Capvaxive are adults aged 19 years and older who have begun their pneumococcal vaccine series with 13-valent PCV (PCV13) but have ...

Related: What Is Pneumococcal Meningitis? Merck’s first pneumonia vaccine, Pneumovax 23, received FDA approval in 1983, and ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

CAPVAXIVE is Merck's approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

There are four vaccines now in use. The U.S. Food and Drug Administration this year approved the newest — Merck’s Capvaxive, ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.